The purpose of this study is determination the effectiveness of vitamin D compared to placebo in vitiligo patients treated with Narrow Band UVB (NBUVB) in a PILOT, randomized, double-blind, single-center study. Inclusion criteria: patients with generalized Vitiligo or skin involvement more than or equal to five percent of the body surface. Exclusion criteria: patients with hemodialysis and renal failure, age less than 6 years, phototherapy sessions of less than 2 times a week. Randomization will be performed using the blocks of size 6, through block randomization method. After checking basic parameters like Ca, BUN, Cr, 25-OH VIT D, patients will be treated with placebo or vitamin D, 50000 units, orally, once every two weeks for two months. Ca, BUN, Cr and 25-OH VIT D will be measured again at 10th week after treatment. Patients will be visited monthly and photography will be done at the end of the second month.
Interventions: Initially, all patients will be treated by NBUVB at the radiation dose of 0.3 J/CM2, twice a week. The dose will be increased by 20% per visit until skin burning or pain will occur. When symptomatic erythema will occur, phototherapy will be stopped until the lesions get healed. Phototherapy will be done twice a week up to 20 weeks. Patients will be followed up for 2 months for to evaluate relapse and treatment outcomes. Patients will be examined at the beginning and at the end of the treatment course and VASI (Vitiligo area severity index) will be calculated in order to assess the extent of their skin involvement.